Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Summit Therapeutics Mulls Additional Trial For Its Once Failed Infection Candidate

Summit Therapeutics Inc (NASDAQ:SMMT) provided an update on the clinical development of ridinilazole, its lead Phase 3 product candidate for Clostridioides…
byVandana Singh
July 14, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Summit Therapeutics Inc (NASDAQ:SMMT) provided an update on the clinical development of ridinilazole, its lead Phase 3 product candidate for Clostridioides difficile infection (C. diff. infection or CDI).
  • This week, Summit and the FDA held a Type C meeting during which Summit discussed certain data from the Ri-CoDIFy Phase 3 trial.
  • Related: Summit Therapeutics’ Infection Candidate Flunks In Head-To-Head Trial.
  • The FDA and Summit discussed a possible pathway to advance ridinilazole to achieve marketing authorization. This pathway would involve reasonable efforts that would likely involve at least one additional clinical trial. The company plans to explore this possibility.
  • The company also plans to share the results from Ri-CoDIFy Phase 3 trial through an oral abstract presentation at IDWeek 2022 in October. 
  • Price Action: SMMT shares are up 1.85% at $0.97 during the market session on the last check Thursday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Trump’s Defiance, Fed Faces Destructive Blame, Tesla’s Growing Autopilot Issues And More: 5 Key Stories From The Weekend

By Shanthi Rexaline
June 12, 8:36 AM
With the first-quarter reporting season and the debt ceiling impasse now in the rearview, all eyes are now on the June meeting of the Federal Open Market Committee, the policy-setting arm of the central bank. The past two days also witnessed a bloodbath in the cryptocurrency market. Here's a recap of a few major headlines you may have missed over the weekend:

AAPL